Subgroups
Bayer HealthCare
-
Friday - May 24, 2013
Not intended for U.S. and UK Media
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant » more
-
Wednesday - May 22, 2013
Johannes Schubmehl appointed CIO of Bayer HealthCare » more
-
Monday - May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) » more
-
Friday - May 17, 2013
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan » more
-
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer » more
-
Friday - May 10, 2013
Bayer HealthCare Demonstrates Successful Integration of the Company’s Largest-Ever Animal Health Acquisition » more
-
Wednesday - May 8, 2013
Not intended for U.S. and UK Media - The American Thoracic Society International Conference 2013:
Bayer to Present Data on Pulmonary Hypertension Research at the ATS International Conference 2013 in Philadelphia
Interim Analysis from Long-Term Extension Study PATENT-2 Phase III / Hemodynamic data and clinical correlation from CHEST-1 Phase III / New Data Sets from Pivotal PATENT-1 Phase III » more
-
Wednesday - May 8, 2013
Bayer HealthCare enables new online resource to fight vector-borne diseases
New canine vector-borne disease webinar will support veterinarians to diagnose and treat vector-borne diseases which can also be transmitted to humans » more
-
Tuesday - May 7, 2013
Not intended for U.S. and UK Media - Cardiovascular Disease Prevention:
Bayer HealthCare joins forces with Stroke Alliance for Europe to prevent Cardiovascular Disease
International opinion leaders raise awareness for societal burden resulting from cardiovascular disease » more
-
Monday - May 6, 2013
Not intended for U.S. and UK Media
Bayer HealthCare Presents New Incubator Model for Biotech Startup Companies in Berlin
Second CoLaborator with dedicated lab space now at Bayer HealthCare Research & Development Center in Berlin / Shared lab space for promising life science startup companies to help them get their start » more
-
Friday - May 3, 2013
Not intended for UK Media
Bayer Provides Update on Phase II/III Trial of BAY 86-6150 » more
-
Monday - April 29, 2013
Not intended for UK media - Strategic expansion of Women’s Health business:
Bayer to acquire Conceptus, Inc.
Adds Essure®, the only non-surgical permanent birth control method, to Bayer’s contraception portfolio » more
-
Friday - April 26, 2013
Annual Stockholders' Meeting 2013 » more
-
Thursday - April 25, 2013
First quarter of 2013:
Bayer: Life Sciences off to a good start in anniversary year
New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed » more
-
Tuesday - April 16, 2013
Not intended for U.S. and UK Media
First Patient Enrolled in Global Phase III Program Evaluating Bayer’s Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia
Treatments to complement current standard of care urgently needed as morbidity and mortality is significant in this patient population » more
-
Wednesday - April 10, 2013
Immunotherapies against cancer:
Bayer HealthCare to broaden strategic alliance with German Cancer Research Center
Joint immunotherapy research laboratory at the National Center for Tumor Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled to start in the middle of 2013 / Additional investments of up to €3 million per year » more
-
Monday - April 8, 2013
Not intended for U.S. and UK Media
U. S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications » more
-
Friday - April 5, 2013
Not intended for U.S. and UK Media - 104th Annual Meeting American Association for Cancer Research
Bayer to Present New Data on Growing Oncology Pipeline
New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development / Numerous Oral and Poster Presentations Highlight Bayer’s Advancing Oncology Portfolio » more
Copyright @ Bayer AG
Search
Publications
research – The Bayer Scientific Magazine
Stockholders' Newsletter
Annual Report
Sustainable Development Report
Publications Overview
Newsletter
Events
Download Center - Selection